Search hospitals > New York > Staten Island
Richmond Behavioral Associates
Claim this profileStaten Island, New York 10312
Global Leader in Alzheimer's Disease
Global Leader in Depression
Conducts research for Major Depressive Disorder
Conducts research for Autism
Conducts research for Schizophrenia
105 reported clinical trials
4 medical researchers
Summary
Richmond Behavioral Associates is a medical facility located in Staten Island, New York. This center is recognized for care of Alzheimer's Disease, Depression, Major Depressive Disorder, Autism, Schizophrenia and other specialties. Richmond Behavioral Associates is involved with conducting 105 clinical trials across 55 conditions. There are 4 research doctors associated with this hospital, such as Mark DiBuono, MD, Matt DiBuono, MD, Adam Smith, PhD, and Mark Vincent DiBuono.Area of expertise
1Alzheimer's Disease
Global LeaderAβ1-42 positive
ApoE
APOE ε4 positive
2Depression
Global LeaderMGH-ATRQ
serotonin
norepinephrine
Top PIs
Mark DiBuono, MDRichmond Behavioral Associates3 years of reported clinical research
Studies Alzheimer's Disease
Studies Agitation
10 reported clinical trials
12 drugs studied
Matt DiBuono, MDRichmond Behavioral Associates1 year of reported clinical research
Studies Pervasive Developmental Disorders
Studies Autism Spectrum Disorder
2 reported clinical trials
1 drug studied
Adam Smith, PhDRichmond Behavioral Associates1 year of reported clinical research
Studies Schizophrenia
1 reported clinical trial
1 drug studied
Mark Vincent DiBuonoRichmond Behavioral Associates3 years of reported clinical research
Studies Alzheimer's Disease
1 reported clinical trial
1 drug studied
Clinical Trials running at Richmond Behavioral Associates
Schizophrenia
Alzheimer's Disease
Dementia
Psychomotor Agitation
Opioid Use Disorder
Autism
Agitation in Dementia
Obsessive-Compulsive Disorder
Agitation
Alzheimer's Dementia
Long-term Safety of Iclepertin
for Schizophrenia
This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term. Participants take Iclepertin as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia. Participants are in the study for a little more than 1 year. During this time, they visit the study site about 13 times and get about 9 phone calls from the study team. The doctors collect information on any health problems of the participants. Doctors also regularly check the participants' symptoms of schizophrenia.
Recruiting2 awards Phase 35 criteria
KarXT
for Schizophrenia
This trial tests KarXT, a combination of two drugs, for people who haven't improved with their current treatment. KarXT aims to balance brain functions and reduce side effects. The study will look at improvements in health and daily life. KarXT has shown positive results in earlier tests.
Recruiting1 award Phase 321 criteria
Iclepertin
for Schizophrenia
This trial tests if a medicine called Iclepertin can help improve memory and learning in adults with schizophrenia. Participants take Iclepertin daily while continuing their usual medication. Doctors regularly check their mental abilities and health throughout the study. Iclepertin is being studied for its potential to improve cognitive functions in schizophrenia.
Recruiting1 award Phase 311 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Richmond Behavioral Associates?
Richmond Behavioral Associates is a medical facility located in Staten Island, New York. This center is recognized for care of Alzheimer's Disease, Depression, Major Depressive Disorder, Autism, Schizophrenia and other specialties. Richmond Behavioral Associates is involved with conducting 105 clinical trials across 55 conditions. There are 4 research doctors associated with this hospital, such as Mark DiBuono, MD, Matt DiBuono, MD, Adam Smith, PhD, and Mark Vincent DiBuono.